Effect of a Hydrolyzed Rice Protein-based Formula on Growth, Tolerance, and Health-related Quality of Life in Infants With Cow's Milk Protein Allergy: a Randomized Nutritional Clinical Study

Status: Recruiting
Location: See all (19) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The main purpose of this study is to demonstrate that the growth of infants fed with the Test Formula is non-inferior those fed with the Control Formula. The study will also evaluate the gastrointestinal tolerance, quatliy of life and acceptability of the new rice protein-based formula in infants with cow's milk protein allergy (CMPA).

Eligibility
Participation Requirements
Sex: All
Maximum Age: 8 months
Healthy Volunteers: f
View:

• Written informed consent has been obtained from at least one parent (or legally acceptable representative \[LAR\]), if applicable)

• Infant gestational age ≥ 37 completed weeks

• Infant birth weight of ≥ 2.5 kg and ≤ 4.5 kg

• Singleton birth

• Infant age ≤ 8 months

• Mother has previously decided to fully formula-feed, and infant is no longer breastfeeding or receiving breast milk

• Suspected CMPA as per standard clinical practice and in conjunction with at least 2 symptoms present from the list shown below:

‣ Inconsolable crying, regurgitation, liquid stools or constipation, skin atopic lesion, cow's milk provoked temporary urticaria/angioedema or vomiting, bloody streaks in stool, or respiratory symptoms

⁃ For diagnosis based on either a positive IgE blood test, skin prick test or food challenge, only at least 1 symptom from above list needs to be present

• Infant is receiving a strict cow's milk elimination diet and will continue receiving this diet until the completion of the study

• Infant's parent(s)/LAR is of legal age of majority, must have parental authority, must understand the informed consent form and other study documents, and is willing and able to fulfill the requirements of the study protocol

Locations
Other Locations
Germany
Charité Universitätsmedizin Berlin
RECRUITING
Berlin
Italy
Azienda Ospedaliera Universitaria Federico II
RECRUITING
Naples
Azienda Ospedaliero Universitaria di Parma
RECRUITING
Parma
AOUP Ospedale Santa Chiara
COMPLETED
Pisa
Ospedale Pediatrico Bambino Gesu
NOT_YET_RECRUITING
Rome
AO Ordine Mauriziano
RECRUITING
Turin
Poland
Poliklinika Ginekologiczno-Położnicza Arciszewscy
RECRUITING
Bialystok
Centrum Medyczne Pratia
RECRUITING
Bydgoszcz
IN-VIVO Bydgoszcz
RECRUITING
Bydgoszcz
Prywatna Praktyka Lekarska Gabinet Pediatryczno-Alergologiczny
RECRUITING
Bydgoszcz
Vitamed Galaj i Cichomski
RECRUITING
Bydgoszcz
BioMedical Centers
RECRUITING
Janki
Centrum Medyczne Plejady
COMPLETED
Krakow
Jagiellonian University Medical College
RECRUITING
Krakow
Wojewodzki Szpital Specjalistyczny im. M. Kopernika
RECRUITING
Lodz
ETG Lublin
RECRUITING
Lublin
Korczowski Bartosz Gabinet Lekarski
RECRUITING
Rzeszów
Alergo-Med Specjalistyczna Przychodnia Lekarska
RECRUITING
Tarnów
University Hospital of Warsaw
COMPLETED
Warsaw
Contact Information
Primary
Anthony de COZAR
anthony.decozar@rd.nestle.com
+41762627426
Time Frame
Start Date: 2024-10-25
Estimated Completion Date: 2026-08
Participants
Target number of participants: 104
Treatments
Experimental: Test Formula
Hydrolyzed rice protein formula
Active_comparator: Control Formula
Commercially available extensively hydrolyzed cow's milk formula
Related Therapeutic Areas
Sponsors
Leads: Société des Produits Nestlé (SPN)

This content was sourced from clinicaltrials.gov